申请人:Eli Lilly and Company
公开号:US04820723A1
公开(公告)日:1989-04-11
The instant invention provides disubstituted tetrazoles that antagonizes the effect of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof in selected tissues. The disubstituted tetrazoles are used in pharmaceutical formulations and methods of treatment of conditions caused by excessive release or production of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof. Such conditions include an immediate hypersensitivity reaction of the type represented by asthma, or by shock or other adverse cardiovascular effects.
本发明提供了对白三烯C.sub.4、D.sub.4或E.sub.4或其任意组合在特定组织中的作用具有拮抗作用的二取代四唑化合物。这些二取代四唑化合物用于制药配方和治疗由白三烯C.sub.4、D.sub.4或E.sub.4或其任意组合引起的疾病的方法。这些疾病包括哮喘、休克或其他不良心血管效应等立即过敏反应。